Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2015

01-03-2015 | Research Article

RETRACTED ARTICLE: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells

Authors: R. H. Xu, L. Y. Zheng, D. L. He, J. Meng, L. P. Xia, X. B. Hao, Z. Z. Zhang

Published in: Clinical and Translational Oncology | Issue 3/2015

Login to get access

Abstract

Objective

To explore the expression profile of miRNAs during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma cells (HCC).

Methods

Proliferation of rat HOCs was induced by chemical carcinogen, 3′-methyl-4-dimethylaminoazobenzene (3′-Me-DAB) in male rats. By using Percoll density gradient centrifugation method, HOCs were isolated, followed by continuous cultivation in vitro. The isolated HOCs were identified via Thy-1 and C-kit detection under laser scanning confocal microscope. Total miRNA was then extracted from HOCs during cell differentiation for microarray hybridization. Differentially expressed miRNAs among the indicated time points were identified. The target genes of identified miRNAs were predicted using PicTar, Target-Scan, and miRanda; then the functions and pathways of the genes were enriched. Y chromosome-specific polymerase chain reaction (PCR) technique was utilized to trace the differentiation of the male HOCs in carcinogen-induced HCC of female rats.

Results

It was shown that isolated HOCs expressed stem cells markers of Thy-1 and C-kit in cytoplasm and membrane. Among 1,210 miRNAs identified, 22 were differentially expressed (P < 0.05, fold change ≥2), including 19 up-regulated and 3 down-regulated ones. The predicted target genes of these miRNAs were enriched in several functions, including axon guidance, angiogenesis, post-transcriptional protein modification, and small molecular metabolism. For PCR-based SRY detection, HCC genomic DNA of female rats from the experimental group displayed the same PCR product as that from normal male rat.

Conclusion

Differentially expressed miRNAs exerted important roles during the differentiation process of HOCs to HCC.
Literature
1.
2.
Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353(17):1793–801.CrossRefPubMed
3.
Shi Y, Liu C, Liu X, Tang DG, Wang J. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014;9(3):e90022.PubMedCentralCrossRefPubMed
4.
Özata DM, Xie H, Lindforss U, Olivecrona H, Lui W-O. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol. 2011;39:311–8.
5.
6.
Xing F, Wu K, Watabe K. MicroRNAs in cancer stem cells: new regulators of stemness. Curr Pharm Des. 2014;28:28.
7.
Nagel R, le Sage C, Diosdado B, van der Waal M, Vrielink JAO, Bolijn A, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68(14):5795–802.CrossRefPubMed
8.
9.
10.
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed
11.
12.
Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol. 2011;7(1):16.
13.
14.
15.
Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis. 2002;23(3):435–45.CrossRefPubMed
16.
Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006;86(12):1272–84.CrossRefPubMed
17.
Sirica AE, Cihla HP. Isolation and partial characterizations of oval and hyperplastic bile ductular cell-enriched populations from the livers of carcinogen and noncarcinogen-treated rats. Cancer Res. 1984;44(8):3454–66.PubMed
18.
Sinclair A, Berta P, Palmer M, Hawkins J, Griffiths B, Palmer M. A gene from the human sex-determining region encodes a protein with. Nature. 1990;346(6281):240–4.CrossRefPubMed
19.
Eisenreich A, Leppert U. The impact of microRNAs on the regulation of tissue factor biology. Trends Cardiovasc Med. 2013;24(3):129–32.
20.
21.
22.
Lin S-L, Chang DC, Chang-Lin S, Lin C-H, Wu DT, Chen DT, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA. 2008;14(10):2115–24.PubMedCentralCrossRefPubMed
23.
Bourguignon LY, Wong G, Earle C, Chen L. Hyaluronan-CD44v3 interaction with Oct4–Sox2–Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012;287(39):32800–24.PubMedCentralCrossRefPubMed
24.
Qian N-S, Liu W-H, Lv W-P, Xiang X, Su M, Raut V, et al. Upregulated MicroRNA-92b regulates the differentiation and proliferation of EpCAM-positive fetal liver cells by targeting C/EBPß. PLoS One. 2013;8(8):e68004.PubMedCentralCrossRefPubMed
25.
Qi J, Yu J-Y, Shcherbata HR, Mathieu J, Wang AJ, Seal S, et al. microRNAs regulate human embryonic stem cell division. Cell Cycle (Georgetown, Tex). 2009;8(22):3729.
26.
Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009;50(1):113–21.CrossRefPubMed
27.
Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008;123(7):1616–22.CrossRefPubMed
28.
Xia H, Ooi LLP, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 2012;7(9):e44206.PubMedCentralCrossRefPubMed
29.
Wong CCL, Wong CM, Tung EKK, Au SLK, Lee JMF, Poon RTP, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140(1):322–31.CrossRefPubMed
30.
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol. 2012;84(3):320–30.CrossRefPubMed
31.
Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet. 2013;45(1):98–103.CrossRefPubMed
32.
Jangravi Z, Alikhani M, Arefnezhad B, Sharifi Tabar M, Taleahmad S, Karamzadeh R, et al. A fresh look at the male-specific region of the human Y chromosome. J Proteome Res. 2012;12(1):6–22.
33.
Eglitis MA, Mezey É. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci. 1997;94(8):4080–5.PubMedCentralCrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells
Authors
R. H. Xu
L. Y. Zheng
D. L. He
J. Meng
L. P. Xia
X. B. Hao
Z. Z. Zhang
Publication date
01-03-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1218-2

Other articles of this Issue 3/2015

Clinical and Translational Oncology 3/2015 Go to the issue

Educational Series – Blue Series

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Research Article

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies

Research Article

MicroRNA-10b indicates a poor prognosis of non-small cell lung cancer and targets E-cadherin

Research Article

Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study

Research Article

Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions

Review Article

Appendiceal carcinoid tumor in children: implications for less radical surgery?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits